@jadafo

Everything changes — don’t be afraid.

 Seattle, WA
Joined March 2010
  • Tweets97
  • Following180
  • Followers99
3Media
We are Stylus Medicine - an in vivo genetic medicines company with a bold vision to reimagine and expand the reach of transformative genetic medicines, starting with in vivo CAR-T therapies. Learn more: businesswire.com/news/home/2…
2
2
19
882
Exclusive: Patrick Hsu’s startup Stylus Medicine launches, looks beyond CRISPR for gene insertion tech - endpts.com/exclusive-patrick…

Exclusive: Patrick Hsu startup launches, looks beyond CRISPR for gene insertion technology

Stylus Medicine, a startup founded by Patrick Hsu, has raised $85 million to develop a suite of technologies that it believes will help solve some of the biggest and most competitive challenges in...

endpoints.news
68
Jason Fontenot retweeted
Simon Mead@smead214 Mar 2025
Zinc Finger Repressors mediate widespread PRNP lowering in the nonhuman primate brain and profoundly extend survival in prion disease mice | bioRxiv. Impressive work, exciting prospect for human study. biorxiv.org/content/10.1101/…

Zinc Finger Repressors mediate widespread PRNP lowering in the nonhuman primate brain and profoun...

Prion disease is a rapidly progressing and invariably fatal neurodegenerative disorder with no approved treatment. The disease is caused by the self-templated misfolding of the prion protein (PrP)...

biorxiv.org
1
7
27
2,535
Interested in our innovative approach to use iPSCs as a renewable source of allogeneic cells to enable Treg cell therapy manufacturing at scale? Helen Fong, Sangamo's Sr. Scientist joins the @FOCISimmunology Meeting for an oral presentation. Learn more: bit.ly/3J2s9CS
2
3
9
1,843
It’s the last day at #ASGCT23 and we’re excited to wrap up a total of 14 presentations featuring progress across our pipeline. For the latest on all of our presentations, visit our website: bit.ly/43mWO5R
2
2
14
2,151
Today we’re showcasing our Viral Delivery Capabilities for Neurology. To discover how our cutting-edge delivery science is progressing, visit the website: bit.ly/43mWO5R #ASGCT23
2
4
10
1,703
Join us at #ASGCT23, where we’ll showcase progress in our pre-clinical programs, including innovations in epigenetic regulation for neurological disorders & our latest advancements in AAV capsid engineering for delivery. See details: bit.ly/3HvNDHD #ZincFinger

Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th...

The Investor Relations website contains information about Sangamo Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.

investor.sangamo.com
2
4
11
1,825
Jason Fontenot retweeted
Adrian Liston@LabListon27 Sep 2022
Using #Tregs no less!
AIMS-RN@aims_rn27 Sep 2022
Job alert from Denise Fitzgerald: Research Technician post available in Fitzgerald lab - come join us in Belfast to figure out how to repair the brain! Closing date 3rd Oct 2022. More details here: hrwebapp.qub.ac.uk/tlive_web…
2
1
8
Jason Fontenot retweeted
Simon Mead@smead216 Sep 2022
Zietler presenting amazing data on Prnp knockdown and prion survival benefits by AAV delivered zinc finger by mouse tail vein injection. Wow this is so exciting. Sangamo therapeutics and the irrepressible Minikel Vallabh team 👏 👏 👏 my surprise good news of #prion2022
1
4
26
Kudos to Bryan Zeitler and the team for the exciting work #prion2022 @SangamoTx
This quoted post is unavailable.
Try viewing anyway · View on X
5
Sangamo AAV engineering is firing on all cylinders
Amy Pooler@amyymelissa17 May 2022
Sr. Scientist David Ojala’s presentation at #ASGCT22 shared exciting progress of our proprietary approach to engineering novel AAV capsids for improved brain delivery. Proud to be part of a scientific team working so hard to improve care options for patients! @SangamoTx
2
1
7
Today at 4pm ET, join our oral presentation at #ASGCT22 to learn how AAV capsids are designed to provide broad CNS access while minimizing exposure to pre-existing anti-AAV antibodies. More: bit.ly/3xKCMW0 #ASGCT #GenomicMedicine #GeneTherapy #CellTherapy
1
4
6
Jason Fontenot retweeted
Amy Pooler@amyymelissa18 May 2022
Love when our @SangamoTX team has an excuse to get together for food, great science talk and lots of laughs. A fun evening with brilliant colleagues! Now enjoying Day 3 of #ASGCT22.
2
2
13
Jason Fontenot retweeted
Amy Pooler@amyymelissa18 May 2022
What an inspirational call to action by keynote #ASGCT22 speaker, former NIH director Francis Collins! He says that gene-based therapies are working, but there are thousands of rare diseases still waiting for treatment. #GenomicMedicine #GeneTherapy @SangamoTx
2
9
The future of cell engineering is here…
Sangamo Therapeutics@SangamoTx16 May 2022
View our poster at #ASGCT22 today to learn more about the efficiency and specificity of multiplexed, epigenetic cell engineering using zinc finger guided transcription factors. Details: bit.ly/3xKCMW0 #ASGCT #GenomicMedicine #GeneTherapy #CellTherapy
1
Sangamo Research taking names…
Sangamo Therapeutics@SangamoTx17 May 2022
Today at #ASGCT22, we will showcase our zinc finger platform's capabilities for high-efficiency base editing in human cells. Learn how: bit.ly/3xKCMW0 #ASGCT #GenomicMedicine #GeneTherapy #CellTherapy
1
Today at #ASGCT22, we will showcase our zinc finger platform's capabilities for high-efficiency base editing in human cells. Learn how: bit.ly/3xKCMW0 #ASGCT #GenomicMedicine #GeneTherapy #CellTherapy
5
1
9
Great work from our AAV engineering team.
Sangamo Therapeutics@SangamoTx18 May 2022
Today at #ASGCT22, we present our AAV capsid poster outlining the CNS delivery via intravenous administration, minimizing exposure to a patient’s pre-existing anti-AAV antibodies. View the abstract: bit.ly/3xKCMW0 #ASGCT #GenomicMedicine #GeneTherapy #CellTherapy
1
4
Jason Fontenot retweeted
Andrew Dunn@AndrewE_Dunn28 Mar 2022
A new story from me — the California biotech Sangamo has dosed the first-ever patient with a new type of cell therapy, called a CAR-Treg. Here's why that could be a big deal in biotech, bringing cell therapy to autoimmune diseases businessinsider.com/exclusiv…

Cell therapy has revolutionized cancer treatment. Now the California biotech Sangamo is trying to...

Sangamo Therapeutics has given its first dose of an experimental T-cell therapy in an effort to treat autoimmune diseases, Insider has learned.

businessinsider.com
5
29
8
137
We're on the cusp of transforming the treatment of autoimmune disease. Exciting times. @SangamoTx nature.com/articles/s41587-0…
4
5
Load more